Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
ALC Stock Forecast 2026-2027
$77.32
Current Price
$39.24B
Market Cap
Buy 21
Hold 7
Sell 1
Wall St Analyst Ratings
Distance to ALC Price Targets
+46.1%
To High Target of $113.00
+25.5%
To Median Target of $97.00
-3.0%
To Low Target of $75.00
ALC Price Momentum
-4.9%
1 Week Change
-2.4%
1 Month Change
-13.1%
1 Year Change
-1.9%
Year-to-Date Change
-22.1%
From 52W High of $99.20
+8.1%
From 52W Low of $71.55
📊 TOP ANALYST CALLS
Did ALC Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Alcon is one of their latest high-conviction picks.
Latest ALC Stock Price Targets & Analyst Predictions
Based on our analysis of 25 Wall Street analysts, ALC has a bullish consensus with a median price target of $97.00 (ranging from $75.00 to $113.00). The overall analyst rating is Strong Buy (8.6/10). Currently trading at $77.32, the median forecast implies a 25.5% upside. This outlook is supported by 21 Buy, 7 Hold, and 1 Sell ratings.
Conversely, the most conservative target is provided by Julien Ouaddour at B of A Securities, suggesting a 3.0% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ALC Analyst Ratings
21
Buy
7
Hold
1
Sell
ALC Price Target Range
Low
$75.00
Average
$97.00
High
$113.00
Current: $77.32
Latest ALC Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ALC.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 9, 2026 | Stifel | Thomas Stephan | Hold | Maintains | $82.00 |
| Feb 26, 2026 | Needham | David Saxon | Buy | Maintains | $100.00 |
| Feb 26, 2026 | Wells Fargo | Larry Biegelsen | Overweight | Upgrade | $97.00 |
| Feb 26, 2026 | Barclays | Matt Miksic | Equal-Weight | Maintains | $90.00 |
| Feb 25, 2026 | BTIG | Ryan Zimmerman | Buy | Maintains | $92.00 |
| Jan 9, 2026 | Stifel | Thomas Stephan | Hold | Downgrade | $80.00 |
| Dec 11, 2025 | B of A Securities | Julien Ouaddour | Underperform | Downgrade | $75.00 |
| Nov 24, 2025 | BTIG | Ryan Zimmerman | Buy | Reiterates | $91.00 |
| Nov 13, 2025 | Baird | Jeff Johnson | Outperform | Maintains | $98.00 |
| Nov 12, 2025 | Needham | David Saxon | Buy | Maintains | $98.00 |
| Nov 11, 2025 | Mizuho | Anthony Petrone | Outperform | Maintains | $100.00 |
| Oct 21, 2025 | Keybanc | Brett Fishbin | Overweight | Maintains | $91.00 |
| Oct 13, 2025 | Barclays | Matt Miksic | Equal-Weight | Initiates | $86.00 |
| Oct 13, 2025 | BTIG | Ryan Zimmerman | Buy | Maintains | $91.00 |
| Sep 29, 2025 | Stifel | Thomas Stephan | Buy | Maintains | $85.00 |
| Aug 21, 2025 | Wells Fargo | Equal-Weight | Maintains | $N/A | |
| Aug 21, 2025 | JP Morgan | David Adlington | Neutral | Downgrade | $77.53 |
| Aug 21, 2025 | Mizuho | Anthony Petrone | Outperform | Maintains | $110.00 |
| Aug 21, 2025 | Stifel | Tom Stephan | Buy | Maintains | $90.00 |
| Aug 21, 2025 | Morgan Stanley | Patrick Wood | Equal-Weight | Maintains | $80.00 |
Alcon Inc. (ALC) Competitors
The following stocks are similar to Alcon based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Alcon Inc. (ALC) Financial Data
Alcon Inc. has a market capitalization of $39.24B with a P/E ratio of 39.6x. The company generates $10.40B in trailing twelve-month revenue with a 9.4% profit margin.
Revenue growth is +8.6% quarter-over-quarter, while maintaining an operating margin of +11.7% and return on equity of +4.5%.
Valuation Metrics
Market Cap
$39.24B
Enterprise Value
$41.90B
P/E Ratio
39.6x
PEG Ratio
-1.7x
Price/Sales
3.8x
Growth & Margins
Revenue Growth (YoY)
+8.6%
Gross Margin
+55.8%
Operating Margin
+11.7%
Net Margin
+9.4%
EPS Growth
-23.6%
Financial Health
Cash/Price Ratio
+4.3%
Current Ratio
2.1x
Debt/Equity
23.8x
ROE
+4.5%
ROA
+2.6%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Alcon Inc. (ALC) Business Model
About Alcon Inc.
What They Do
Global vision care company specializing in eye health.
Business Model
Alcon Inc. operates through two main segments: Vision Care and Surgical. The Vision Care segment generates revenue by selling contact lenses and ocular health products, while the Surgical segment earns money through the sale of surgical equipment and intraocular lenses used in eye surgeries. This diversified product offering allows Alcon to capture significant market share in both consumer and professional healthcare sectors.
Additional Information
Founded in 1945 and based in Geneva, Switzerland, Alcon was previously a subsidiary of Novartis until becoming independent in 2019. The company employs around 25,599 people and has a substantial presence in the eye care market, particularly with its well-known brands like Dailies, Total1, and Air Optix in the U.S. contact lens market.
Company Information
Sector
Healthcare
Industry
Medical Instruments & Supplies
Employees
25,942
CEO
Mr. David J. Endicott
Country
Switzerland
IPO Year
N/A
Website
www.alcon.comAlcon Inc. (ALC) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
5 Medical Instruments Stocks to Buy Amid Huge Short-Term Price Upside
ISRG, GMED, EW, ALC and IRMD show strong short-term upside as AI tools, acquisitions and new product pipelines fuel growth.
Mar 10, 2026
By Nalak Das
Analyst Blog
Latest News
Quick Summary
ISRG, GMED, EW, ALC, and IRMD demonstrate potential short-term growth driven by AI tools, acquisitions, and new product developments.
Why It Matters
Strong short-term upside in ISRG, GMED, EW, ALC, and IRMD indicates potential for stock price increases, driven by AI innovations and strategic growth initiatives.
Source: Zacks Investment Research
Market Sentiment:
Positive
Glaucoma Research Foundation and Alcon Partner to Expand Access to Trusted Glaucoma Education
4 days ago
Quick Summary
The Glaucoma Research Foundation is partnering with Alcon to release updated English and Spanish editions of "Understanding and Living with Glaucoma" and a Spanish audiobook to aid high-risk Hispanic communities.
Why It Matters
The partnership between GRF and Alcon enhances access to glaucoma education for Hispanic communities, potentially increasing demand for eye care services and products, influencing market growth.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Alcon (ALC) and Anavex Life Sciences (AVXL) have shown performance metrics that can be compared to their respective sectors year-to-date.
Why It Matters
Performance comparisons highlight relative strength or weakness, influencing investor sentiment and potential investment decisions in Alcon and Anavex Life Sciences against their sector.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Alcon has successfully implanted over 175 million intraocular lenses (IOLs) worldwide, marking a significant milestone for the company.
Why It Matters
Alcon's milestone of 175 million IOLs implanted signals strong product demand and market leadership, potentially boosting investor confidence and stock performance.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Alcon expects 2026 sales growth in line with market estimates and projects a significant increase in operating margin, driven by anticipated product launches.
Why It Matters
Alcon's forecasted sales growth and expanding operating margin indicate strong future profitability, boosting investor confidence in the company's growth potential and market competitiveness.
Source: Reuters
Market Sentiment:
Positive
Quick Summary
Alcon Inc. (ALC) held its Q4 2025 earnings call, discussing financial results and future outlook. Details of the earnings and strategic plans were shared during the call.
Why It Matters
Alcon Inc.'s Q4 2025 earnings call provides insights into financial performance and future guidance, influencing stock valuation and investment decisions.
Source: Seeking Alpha
Market Sentiment:
Neutral
Frequently Asked Questions About ALC Stock
What is Alcon Inc.'s (ALC) stock forecast for 2026?
Based on our analysis of 25 Wall Street analysts, Alcon Inc. (ALC) has a median price target of $97.00. The highest price target is $113.00 and the lowest is $75.00.
Is ALC stock a good investment in 2026?
According to current analyst ratings, ALC has 21 Buy ratings, 7 Hold ratings, and 1 Sell ratings. The stock is currently trading at $77.32. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ALC stock?
Wall Street analysts predict ALC stock could reach $97.00 in the next 12 months. This represents a 25.5% increase from the current price of $77.32. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Alcon Inc.'s business model?
Alcon Inc. operates through two main segments: Vision Care and Surgical. The Vision Care segment generates revenue by selling contact lenses and ocular health products, while the Surgical segment earns money through the sale of surgical equipment and intraocular lenses used in eye surgeries. This diversified product offering allows Alcon to capture significant market share in both consumer and professional healthcare sectors.
What is the highest forecasted price for ALC Alcon Inc.?
The highest price target for ALC is $113.00 from at , which represents a 46.1% increase from the current price of $77.32.
What is the lowest forecasted price for ALC Alcon Inc.?
The lowest price target for ALC is $75.00 from Julien Ouaddour at B of A Securities, which represents a -3.0% decrease from the current price of $77.32.
What is the overall ALC consensus from analysts for Alcon Inc.?
The overall analyst consensus for ALC is bullish. Out of 25 Wall Street analysts, 21 rate it as Buy, 7 as Hold, and 1 as Sell, with a median price target of $97.00.
How accurate are ALC stock price projections?
Stock price projections, including those for Alcon Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: March 14, 2026 2:05 AM UTC